Companies › GLMD

Galmed Pharmaceuticals Ltd (GLMD)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001595353 · EDGAR filings · Updated 2026-07-28

Galmed Pharmaceuticals Ltd (GLMD) has reported institutional ownership of 2.2%, with 16 institutional managers holding positions valued at $71.2K per the latest 13F reporting period. SEC filings include an active substantial-doubt (going concern) disclosure per the filings.

Filings this week (2)

• 2026-07-28 — Foreign issuer report (6-K) filed
• 2026-07-22 — Foreign issuer report (6-K) filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-16 — Foreign issuer report (6-K) filed
• 2026-07-08 — Foreign issuer report (6-K) filed
• 2026-06-22 — Prospectus supplement (424B3) filed
• 2026-06-22 — Foreign issuer report (6-K) filed

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, Galmed Pharmaceuticals Ltd has 16 institutional holders and institutional ownership of 2.2%.

Insider activity

Insiders reported 0 transactions (0 buys, 0 sells) across 7 reporting insiders, with a net reported value of $0.

Data flags from SEC filings

Related companies

NUCANA PLC (NCNA) · FUNCTIONAL BRANDS INC (MEHA) · NEXENTIS TECHNOLOGIES INC (NXTS) · AGAPE ATP CORP (ATPC) · IMMURON LTD (IMRN) · GRI Bio Inc (GRI)